



3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Rashida A. Karmali

Serial No. : 10/826,083                      Group Art Unit : 1743  
Filed : 04/16/2004                      Examiner : Jill A. Warden  
For : Specimen Collection, processing and analytical Assembly

---

**SECOND DECLARATION OF Rashida A. Karmali Under 37 C.F.R. 1.132**

1. I am the inventor in the above referenced application. I am currently Chief Executive Officer Chief Financial Officer and Chief Scientific Officer of SavviPharm Inc, located in New York, New York. I am beneficial owner of this invention. I have a Ph.D in Biochemistry (1976) and have published over 100 scientific articles.

2. The Advisory Action Before Filing of an Appeal Brief mailed on January 18, 2007, included the following Statements:

*#11. Cost savings and efficiency ....must be supported by a showing of facts, not just conclusions”.*

Response. applicant is amazed that this senior examiner would ask for an economic report on cost savings when one with ordinary skill in the art can clearly understand that a collecting device for 5ml or 10 ml of blood will require a larger tube, larger amounts chemicals and higher prices per tube than a smaller collecting device, smaller amounts of chemicals and lower prices per tube were used to collect < 2ml blood.

Applicant is not only the CEO of her company SavviPharm Inc, but the CFO. However, this examiner finds it hard to believe anything applicant states and labels it as “just conclusions”.

*# 13. Examiner states that she requires more evidence on the refinement of the coating of the capillary in response to the following paragraph in Declaration of 12/09/06:*


---

j) In fact, it was after several attempts that we standardized the coating of the capillary tube so the coating material(s) did not interfere with the drawing of the specimen or block the opening of the capillary tube.

Response: The experiments that we conducted involved dissolving the anticoagulants in either water, alcohol or saline and then layer the internal of the capillary tube. We found that saline and alcohol were not appropriate vehicles to dissolve the anticoagulants because somehow, the capillary suction was slower. We also found that the capillary action was faster when we avoided layering the extreme tip of the capillary.

I hereby declare that all statements made hereto to my knowledge are true, and all statements made on information and beliefs are believed to be true; and further, that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon.

By:



Rashida A. Karmali, Ph.D

Date:

8/19/07



CUSTOMER NO. 000042131

docket no. 134.004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Rashida A. Karmali

Serial No.	:	10/826,083	Group Art Unit :	1743
Filed	:	04/16/2004	Examiner :	Dwayne K. Handy.
For	:	Specimen Collection, processing and analytical Assembly		

---

**DECLARATION OF Rashida A. Karmali Under 37 C.F.R. 1.132**

1. I am the inventor in the above referenced application. I am currently Chief Executive Officer and Chief Scientific Officer of SavviPharm Inc, located in New York, New York. I am beneficial owner of this invention. I have a Ph.D in Biochemistry (1976) and have published over 100 scientific articles.

2. The Final Action dated October 19, 2006 included the following Statements:

*"Applicant's arguments filed 7/21/06 have been fully considered but they are not persuasive. The previous rejection may be summarized as follows; Schramm teaches every element of the claims except for the materials, filter, colored reagents, and coated capillary. Nason provides a teaching of plastic materials, a filter and colored reagents. Liotta provides a coated capillary.*

*"Liotta also teaches the analysis of a sample by colorimetric or optical assay. Applicant has argued that Liotta does not, in fact, disclose the coated capillary. The Examiner disagrees. Liotta recites that a coated vacutainer or coated capillary pipette could be utilized in collecting the sample (column 12, lines 46-67).(emphasis added)"*

Response: I disagree with the examiner's conclusions for the following reasons.

Schramm

a) As indicated above by the Examiner, Schramm does NOT teach 1) materials, 2) filter, 3) colored reagents and 4) coated capillary.

b) In fact, Schramm's device does not have a filter and as such any sample collected will include undesirable debris since the sample is not filtered.

c) Schramm's device does not contain the anticoagulant material in the capillary tube and therefore the blood sample would have to be processed rapidly or else it would coagulate.

d) Schramm's device is not color coded and therefore samples would have to be labeled to identify the treatment in the capillary tube.

Nason

e) Nason is cited for filters, plastic materials, and colored reagents. In col. 5, lines 58-62, Nason describes that the housing is made of plastic. However, plastic is NOT a distinguishing feature in the present invention.

f) Similarly, in col. 9, lines 19-25, Nason describes that the vial 70 is placed in a colorimetric device to measure the color change. However, colorimetric measure of color change is not a distinguishing feature in this invention. The color change in the present invention is recorded more easily, i.e., visually and does not require a device.

g) The filter members 18 and 19 are serially mounted and filter 19 terminates in a rounded contour, col. 8, lines 5-15. Col 9, lines 24-31, cited in the Action, describe optical detection in a device without requiring the vial to be touched. These features are NOT present in the present invention and in fact distinguish it from Nason.

Liotta

h) Liotta does not provide a coated capillary- this is an inaccurate statement. the present invention in no way deals with interference caused by chelating metals. One skilled in the art would not find it advantageous to use Liotta's teachings on method of activating light emission by a photonprotein adapted for use in a diagnostic

assay and providing a substrate having a coated or impregnated with a dried salt of a metal cation and a dried caged metal cation compound to produce a dried metal cation zone.....Claim 1 of Liotta. The mere fact that Liotta mentions the word "capillary" does not make it relevant art.

i) By the Examiner's own admission, Liotta recites a coated vacutainer or coated capillary pipette. Both these devices are different and distinguishable from the capillary tube of the present invention. In fact, coated vacutainers have been known in the art for a long time, and the vacutainer tubes are especially pressurized to draw blood by suction. And pipettes that are coated have been used to draw samples by suction (mouth or rubber tip). However, there is no teaching in the art for capillary tubes being coated with anything and then used for drawing biological samples. This is because a very clean inside surface of the capillary tube is required to create a capillary force for the specimen to be drawn by this capillary force up the tube, and usually in very small volumes.

j) In fact, it was after several attempts that we standardized the coating of the capillary tube so the coating material(s) did not interfere with the drawing of the specimen or block the opening of the capillary tube.

k) One skilled in the art associates a capillary glass tube with the short thin glass tube which is open at both ends. This is used to collect blood, then one end is plugged by heating, and the tube is centrifuged to obtain the hematocrit.

3. Summary of Interview held with Examiner Dwayne Handy on October 16, 2006

I find it necessary to submit my account under Oath, of the Interview because it is at odds with the Examiner's conclusion.

- a) Examiner Handy called at 10.45 am and summarily repeated the rejections made in the Office Action of March 23, 2006. He indicated that the response had addressed two references- Schramm and Nason but he was not convinced that the third reference – Liotta was overcome.
- b) I pointed out that Liotta was entirely a different invention category and that the Examiner was using hindsight in applying it. I also pointed out that the whole invention should be considered and that in fact there was a need for the invention because it allowed collection of small amounts of blood and prevented waste of blood as repeatedly shown in the specification.

- c) Examiner Handy stated that he did not have time to work with me on this and would issue the next Final Action.

Therefore, based on the above arguments there is no basis to maintain the rejections of claims 1-15 and they should be withdrawn.

I hereby declare that all statements made hereto to my knowledge are true, and all statements made on information and beliefs are believed to be true; and further, that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon.

By:

Rashida A. Karmali

Rashida A. Karmali, Ph.D

Date:

12/18/2006



**CERTIFICATE OF Facsimile Transmission**

I hereby certify that this correspondence is transmitted by 571-273-8300 under 37 C.F.R. 1.6  
on October 16, 2006 addressed to: Commissioner for Patents, Alexandria, VA 22313-1450.

Rashida A. Karmali  
Attorney for Applicants

/Rashida A. Karmali/

Signature

10-16-06

TO: Auto-reply fax to 212 651 9654 COMPANY:

**Auto-Reply Facsimile Transmission**

4

TO:

Fax Sender at 212 651 9654

Fax Information

Date Received:

10/16/2006 12:44:05 PM [Eastern Daylight Time]

Total Pages:

4 (including cover page)

**ADVISORY:** This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received  
Cover  
Page

=====&gt;

Oct 16 06 12:52P Rashida A Karmali Esq 21265149654 p.1

**Rashida A. Karmali, Ph.D**  
Tech. & Intellectual PropertyRegistered Patent Attorney  
99 Wall Street, 13<sup>th</sup> Floor  
New York, NY 10005  
www.krashida.comPhone (212) 651-9653  
Fax (212) 651-9654  
Karmali@aol.com**FAX TRANSMISSION**DATE: October 16, 2006  
TO: GROUP 1743  
COMPANY: USPTO  
FAX NO: 571-273-8300  
FROM: RASHIDA A. KARMALI  
No. of Pages:

MESSAGE: INTERVIEW RECORD

**CERTIFICATE OF FACSIMILE TRANSMISSION (37 C.F.R. 1.6)**

I hereby certify that this correspondence is being filed by FACSIMILE

TRANSMISSION at 571-273-8000 addressed to: Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450.

Rashida A. Karmali  

Signature

October 16, 2006  
Date of SignatureThank you For your assistance  
Rashida Karmali